The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial

Autor:	de Wit, Ronald, Herrstedt, J, Rapoport, B, Carides, AD, Guoguang-Ma, J, Elmer, M, Schmidt, C, Evans, JK, Horgan, KJ
Přispěvatelé:	Medical Oncology
Rok vydání:	2004
Zdroj:	European Journal of Cancer, 40, 403-410. Elsevier Ltd.
ISSN:	0959-8049
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=narcis______::0cfc2067e97e2f66381e63452d2efb89 https://pure.eur.nl/en/publications/0d9691c5-7c43-4732-9879-9142eb2feb07 Zobrazit plný text záznamu Full Text from ScienceDirect